Daiichi Sankyo Realigns Japan R&D As Oncology Comes To Fore
Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.
You may also be interested in...
Daiichi Sankyo makes further vaccine business restructuring moves as it emphasizes oncology amid global generic challenges to its former big seller olmesartan.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.